Navigation Links
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Date:2/24/2011

WAYNE, N.J. and EMERYVILLE, Calif., Feb. 24, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer. This Phase 3 trial was initiated based on the results from a cooperative group-sponsored Phase 2 clinical trial evaluating Nexavar in combination with capecitabine in patients with advanced breast cancer.

"This Phase 3 trial is an important milestone in our development of Nexavar as it provides an opportunity to evaluate Nexavar in this patient population," said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. "We look forward to continuing our breast cancer clinical trial program, which includes two ongoing cooperative group-sponsored Phase 2 trials."

Phase 3 Trial Design

The RESILIENCE (Phase 3 TRial Comparing CapecitabinE in Combination with SorafenIb or PLacebo for Treatment of Locally Advanced or MetastatIc HER2–Negative Breast CancEr) trial is a randomized, double-blind, placebo-controlled Phase 3 study planned to enroll 519 patients in more than 20 countries including the United States, Brazil, Japan and Australia. The study will evaluate Nexavar in combination with capecitabine in patients with locally advanced or metastatic HER-2 negative breast cancer who are resistant to or have failed prior taxane and an anthracycline or for whom further anthracycline is not indicated. The primary endpoint of the study is progression-free survival. Secondary endpoints include
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... LEIPZIG, Germany , Sept. 17, 2014 ... entered into an exclusive technology development partnership with ... agents to image CD4+ positive immune T cells. ... capability to precisely diagnose and determine therapeutic options ... The ability to image CD4+ T-cells will also ...
(Date:9/17/2014)... , Sept. 17, 2014   GS1 ... how to implement GS1 Standards to support the ... enhance patient safety and security in the pharmaceutical ... GS1 Standards to U.S. Pharmaceutical Supply Chain Business ... Act , was developed in collaboration with ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... announced that it has earned a $4 million ... AKAO ) associated with the initiation of a ... serious multi-drug resistant (MDR), gram-negative bacterial infections.  The ... study to evaluate the efficacy and safety of ...
Breaking Medicine Technology:ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
(Date:9/18/2014)... Atlanta, GA (PRWEB) September 18, 2014 ... Counselor, recognizes that 1- sometimes, inner beauty has to ... strengths have to be acknowledged in order to be ... , Healing Hearts shows the world how to do ... Counseling and Life Coaching using the Healing Hearts system, ...
(Date:9/18/2014)... Mateo, CA (PRWEB) September 18, 2014 ... archiving solutions, from active, to medium, and even long ... of content for any length of time. This includes ... of machine-produced data. When used together, Nautilus and ASG-Digital ... managing archive content. , "storageFOUNDRY is pleased to ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 Recently, UWDress.com, ... dresses and women’s special occasion outfits, has released its ... In addition, the firm has launched a big sale ... are now available at deeply discounted rates, from 15 ... that the company insists on using comfortable to wear ...
(Date:9/17/2014)... Charlotte, NC (PRWEB) September 18, 2014 ... , U.S. emergency departments treat an estimated 173,285 sports- ... and adolescents every year. Soon, a blood test may ... concussion is and how long recovery will take. ... reported that they have found a way to ...
(Date:9/17/2014)... According to an August 5, ... “Adverse Events Associated with Use of Enhancement Medical's ... use of Expression, a hyaluronic acid product, for ... including discoloration, lumps, bruising, nodules, and swelling. ... cosmetic use include Restylane , Juvéderm, Perlane, ...
Breaking Medicine News(10 mins):Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2
... effort to uncover the medium- and large-scale genetic differences between ... a wide range of diseases, according to a paper by ... published in the May 10, 2007, Nature. The undertaking will ... says amount to as much as five to ten percent ...
... study examines the use of tissue-engineered scaffolding made of cartilage ... replace defective cartilage tissue. ,Cartilage cells are ... the body, where new cartilage tissue is grown along the ... ,The procedure was extremely successful in tested mice as ...
... immune systems of humans and opossums, the famous Australian ... breakthroughs in the understanding and treatment of facial tumours ... in the Australian island state of Tasmania. ... of genetic information of the South American opossum, the ...
... Breakthrough research has offered a clue as to why oral ... in persons not regarded as primary-risk candidates . American scientists ... passes on the human papillomavirus or HPV between partners and ... does not smoke, drink or use any substance known to ...
... study reveals that almost two-thirds of US children ... but very few of them experience post-traumatic stress ... resilience in children, but it also suggests that the ... said William Copeland of Duke University Medical Center, whose ...
... cervical cancer is nearly 100 percent effective against the two ... cases of cervical cancer. Results of a nationwide study of ... of the New England Journal of Medicine. ,But ... three shots of a new HPV vaccine marketed by Merck ...
Cached Medicine News:Health News:Cataloging the Structural Variations in Human Genetics 2Health News:Cataloging the Structural Variations in Human Genetics 3Health News:Treatment of Premature Babies, Opossums Could Help 2Health News:Swallowing The Bitter Pill-Oral Sex Linked To Oral Cancer 2Health News:Two-thirds of US Children Experience Trauma, but Recover Fast 2Health News:Study Shows Continued Success for New HPV Vaccine Against Virus 2
... high-end microplate reader with outstanding sensitivity and ... Fluorescence Intensity - FRET , Fluorescence Polarization ... , Luminescence , , , ... reader with fastest read times. The ultimate ...
GENios Pro, TECANs advanced, multi-functional injector reader offers simultaneous reagent dispensing and detection for monitoring of fast kinetic reactions...
... Throughput Screening (UHTS), Analyst GT delivers ... for smooth transfer of assays into ... all the detection modalities of Analyst ... polarization, time-resolved fluorescence, luminescence, absorbance, as ...
... a fully automated microplate based multi-detection ... principles:, , Fluorescence Polarization , ... , High-Performance Luminescence (flash and glow) ... is designed for the widest possible ...
Medicine Products: